US Alpha Thalassemia Market

ID: MRFR/LS/17741-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026
US Alpha Thalassemia Market Research Report By Type (hemoglobin Bart hydrops fetalis syndrome or Hb Bart syndrome, HbH disease, silent carrier state, trait), By Diagnosis (perinatal testing, prenatal testing, pre-implantation, complete blood count (CBC), DNA testing, prenatal genetic testing, chorionic villus sampling), By Treatment (blood transfusions, iron chelation, bone marrow or stem cell transplant, surgery, gene therapy) and By End-User (hospitals, biotechnological laboratories, diagnostic laboratories, educational research institutes, pharmaceutical industries, others) - Growth & Industry Forecast 2025 To 2035
US Alpha Thalassemia Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)10.16%
2024 Market Size$ 1,020.19 Million
2025 Market Size$ 1,123.84 Million
2035 Market Size$ 2,957.64 Million
Key Players
Novartis
Bristol-Myers Squibb
Amgen
Pfizer
Roche
GSK
Trends
  • Emergence of Gene Therapy
  • Increased Awareness and Screening
  • Collaborative Research Efforts
Opportunities
  • Government Initiatives and Funding
  • Growing Demand for Genetic Testing
  • Advancements in Treatment Modalities
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Type (USD Million)
      1. 4.1.1 Hb Bart syndrome
      2. 4.1.2 HbH disease
      3. 4.1.3 silent carrier state
      4. 4.1.4 trait
    2. 4.2 Construction, BY Diagnosis (USD Million)
      1. 4.2.1 perinatal testing
      2. 4.2.2 prenatal testing
      3. 4.2.3 pre-implantation
    3. 4.3 Construction, BY Treatment (USD Million)
      1. 4.3.1 blood transfusions
      2. 4.3.2 iron chelation
      3. 4.3.3 bone marrow or stem cell transplant
      4. 4.3.4 surgery
      5. 4.3.5 gene therapy
    4. 4.4 Construction, BY End-User (USD Million)
      1. 4.4.1 hospitals
      2. 4.4.2 biotechnological laboratories
      3. 4.4.3 diagnostic laboratories
      4. 4.4.4 educational research institutes
      5. 4.4.5 pharmaceutical industries
      6. 4.4.6 others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Amgen (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Roche (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 GSK (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Celgene (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Vertex Pharmaceuticals (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 US MARKET ANALYSIS BY TREATMENT
    5. 6.5 US MARKET ANALYSIS BY END-USER
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    16. 6.16 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
    18. 6.18 CONSTRUCTION, BY END-USER, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY END-USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
      4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Alpha Thalassemia Market Segmentation

US Alpha Thalassemia Market By Type (USD Million, 2025-2035)

  • Hb Bart syndrome
  • HbH disease
  • silent carrier state
  • trait

US Alpha Thalassemia Market By Diagnosis (USD Million, 2025-2035)

  • perinatal testing
  • prenatal testing
  • pre-implantation

US Alpha Thalassemia Market By Treatment (USD Million, 2025-2035)

  • blood transfusions
  • iron chelation
  • bone marrow or stem cell transplant
  • surgery
  • gene therapy

US Alpha Thalassemia Market By End-User (USD Million, 2025-2035)

  • hospitals
  • biotechnological laboratories
  • diagnostic laboratories
  • educational research institutes
  • pharmaceutical industries
  • others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.